FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308396323> ?p ?o ?g. }

• W4308396323 abstract "<h3>Background</h3> Despite recent advances with immunotherapy in head and neck squamous cell carcinoma (HNSCC), many patients progress and develop resistance to checkpoint inhibitors. Aryl hydrocarbon receptor (AHR) is a ligand-activated nuclear transcription factor that regulates the activity of multiple innate and adaptive immune cells. Kynurenine, a ligand generated from tryptophan by IDO1 and TDO2, binds AHR and leads to a net immunosuppressive tumor microenvironment. HNSCC has been found to have high prevalence of nuclear AHR protein expression, indicative of active AHR signaling, making AHR an attractive therapeutic target. IK-175 is an oral selective, small molecule that is being developed as potential first-in-class AHR inhibitor for the treatment of cancer. Given the role of AHR in mediating immunosuppression, IK-175 may overcome the immunosuppressive effects driving resistance to PD-1 inhibitors in HNSCC and improve the clinical activity of nivolumab. <h3>Methods</h3> This is a phase 1b, open-label, multicenter, dose-expansion study of IK-175 in combination with nivolumab in adult patients with primary programmed cell death-1 (PD-1) inhibitor resistant metastatic or locally incurable, recurrent head and neck squamous cell carcinoma (HNSCC). IK-175 is administered orally at a dose of 600mg QD (Cohort 1) or 450mg q12h (Cohort 2) in 28 day-cycles in combination with nivolumab (480 mg q4w on Day 1 of every cycle). AHR nuclear localization is being studied as a potential predictive biomarker in patients with HNSCC. The study will enroll unselected HNSCC patients as well as an enriched population that includes patients with AHR + tumors as determined by immunohistochemistry. Key eligibility criteria include patients with histologically confirmed advanced HNSCC that have progressed within 12 weeks of initiation of a PD-1 inhibitor, whether administered alone or in combination with chemotherapy. The primary objectives are to determine the safety, tolerability, and preliminary antitumor activity (ORR, DCR, and DOR) of IK-175 in combination with nivolumab. Secondary objectives are to evaluate the pharmacokinetics of IK-175 and its active metabolites and to assess additional parameters of preliminary antitumor activity (PFS). Key exploratory objectives are to evaluate pharmacodynamic effects on paired tumor biopsies and peripheral immune cells, to assess candidate baseline biomarkers, and correlative analyses of tumor AHR nuclear localization with disease response. Estimated enrollment is approximately 54 patients; the study started in July 2022. <h3>Trial Registration</h3> NCT05472506 <h3>Ethics Approval</h3> The study was approved by Advarra Central IRB, approval number MOD01366597" @default.
• W4308396323 created "2022-11-11" @default.
• W4308396323 creator A5000382039 @default.
• W4308396323 creator A5033097087 @default.
• W4308396323 creator A5058973099 @default.
• W4308396323 creator A5070559391 @default.
• W4308396323 creator A5075768261 @default.
• W4308396323 creator A5079585064 @default.
• W4308396323 creator A5088915722 @default.
• W4308396323 date "2022-11-01" @default.
• W4308396323 modified "2023-09-25" @default.
• W4308396323 title "680 A phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer" @default.
• W4308396323 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0680" @default.
• W4308396323 hasPublicationYear "2022" @default.
• W4308396323 type Work @default.
• W4308396323 citedByCount "0" @default.
• W4308396323 crossrefType "proceedings-article" @default.
• W4308396323 hasAuthorship W4308396323A5000382039 @default.
• W4308396323 hasAuthorship W4308396323A5033097087 @default.
• W4308396323 hasAuthorship W4308396323A5058973099 @default.
• W4308396323 hasAuthorship W4308396323A5070559391 @default.
• W4308396323 hasAuthorship W4308396323A5075768261 @default.
• W4308396323 hasAuthorship W4308396323A5079585064 @default.
• W4308396323 hasAuthorship W4308396323A5088915722 @default.
• W4308396323 hasBestOaLocation W43083963231 @default.
• W4308396323 hasConcept C121608353 @default.
• W4308396323 hasConcept C126322002 @default.
• W4308396323 hasConcept C143998085 @default.
• W4308396323 hasConcept C2776107976 @default.
• W4308396323 hasConcept C2776530083 @default.
• W4308396323 hasConcept C2776833033 @default.
• W4308396323 hasConcept C2777701055 @default.
• W4308396323 hasConcept C2780030458 @default.
• W4308396323 hasConcept C502942594 @default.
• W4308396323 hasConcept C71924100 @default.
• W4308396323 hasConceptScore W4308396323C121608353 @default.
• W4308396323 hasConceptScore W4308396323C126322002 @default.
• W4308396323 hasConceptScore W4308396323C143998085 @default.
• W4308396323 hasConceptScore W4308396323C2776107976 @default.
• W4308396323 hasConceptScore W4308396323C2776530083 @default.
• W4308396323 hasConceptScore W4308396323C2776833033 @default.
• W4308396323 hasConceptScore W4308396323C2777701055 @default.
• W4308396323 hasConceptScore W4308396323C2780030458 @default.
• W4308396323 hasConceptScore W4308396323C502942594 @default.
• W4308396323 hasConceptScore W4308396323C71924100 @default.
• W4308396323 hasLocation W43083963231 @default.
• W4308396323 hasOpenAccess W4308396323 @default.
• W4308396323 hasPrimaryLocation W43083963231 @default.
• W4308396323 hasRelatedWork W2141197908 @default.
• W4308396323 hasRelatedWork W2768318314 @default.
• W4308396323 hasRelatedWork W2924003728 @default.
• W4308396323 hasRelatedWork W2974748062 @default.
• W4308396323 hasRelatedWork W3000701650 @default.
• W4308396323 hasRelatedWork W3090002302 @default.
• W4308396323 hasRelatedWork W3202309647 @default.
• W4308396323 hasRelatedWork W4221021748 @default.
• W4308396323 hasRelatedWork W4312075079 @default.
• W4308396323 hasRelatedWork W4321786945 @default.
• W4308396323 isParatext "false" @default.
• W4308396323 isRetracted "false" @default.
• W4308396323 workType "article" @default.